ESC 365 - Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation

ESC Premium Access

Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation

Session: Poster Session 3 - Antiplatelet therapy

Topic: Anticoagulants

Speaker: Assistant Professor F. Ricci (Chieti, IT)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Assistant Professor Fabrizio Ricci

G. d Annunzio University of Chieti-Pescara, Chieti (Italy)

2 presentations

0 follower

4 more presentations in this session

A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study

Speaker: Doctor I. Lianos (London, GB)

Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis

Speaker: Doctor D. Errigo (Turin, IT)

Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischaemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients

Speaker: Doctor J. Li (Beijing, CN)

Bleedings during antithrombotic therapy: a blessing in disguise

Speaker: Doctor D. Cosmi (Perugia, IT)

Access the full session

Poster Session 3 - Antiplatelet therapy

Speakers: Assistant Professor F. Ricci, Doctor I. Lianos, Doctor D. Errigo, Doctor J. Li, Doctor D. Cosmi

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources